Molecular structure of Anagrelide hydrochloride, CAS Number: 58579-51-4
Anagrelide hydrochloride (CAS 58579-51-4)
See product citations (1)
Alternate Names:
Agrylin
Application:
Anagrelide hydrochloride is a potent type III phosphodiesterase inhibitor
CAS Number:
58579-51-4
Molecular Weight:
292.55
Molecular Formula:
C10H7Cl2N3O•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Anagrelide hydrochloride is a potent PDE3 (type III phosphodiesterase) inhibitor (IC50 = 36 nM). It produces thrombocytopenic effects via inhibition of megakaryocyte maturation and inhibits platelet aggregation. Studies have shown that it binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), which is involved in the production of thromboxane A2. It can also reduce the aggregation of platelets in response to various agonists, including collagen, thrombin, and ADP. In addition, Anagrelide hydrochloride reduces the production of other pro-inflammatory molecules, such as prostaglandins and leukotrienes. In vitro studies have been used to investigate its mechanism of action, biological activity, and biochemical and physiological effects.
Anagrelide hydrochloride (CAS 58579-51-4) References
- Anagrelide: a novel agent for the treatment of myeloproliferative disorders. | Pescatore, SL. and Lindley, C. 2000. Expert Opin Pharmacother. 1: 537-46. PMID: 11249536
- Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. | Mazur, EM., et al. 1992. Blood. 79: 1931-7. PMID: 1562721
- Cytomegalovirus ischemic colitis: a near-fatal presentation of HIV infection. | Lin, RK., et al. 2004. AIDS Patient Care STDS. 18: 497-500. PMID: 15630769
- [Diagnostic and therapeutic management of essential thrombocythemia in children]. | Mitura-Lesiuk, M., et al. 2004. Med Wieku Rozwoj. 8: 834-8. PMID: 15858255
- [Anagrelide in the treatment of thrombocythemia essential (ET)]. | Mazur, G., et al. 2004. Pol Arch Med Wewn. 112: 1445-50. PMID: 15962609
- Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. | Wang, G., et al. 2005. Br J Pharmacol. 146: 324-32. PMID: 16041400
- [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]. | Penka, M., et al. 2006. Vnitr Lek. 52: 498-503. PMID: 16771099
- Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. | Reilly, JT. 2009. Hematology. 14: 1-10. PMID: 19154658
- Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Anagrelide Hydrochloride. | Pujeri, SS., et al. 2012. Sci Pharm. 80: 567-79. PMID: 23008806
- Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. | Gillespie, E. 1988. Biochem Pharmacol. 37: 2866-8. PMID: 2456068
- Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. | Espasandin, YR., et al. 2015. J Thromb Haemost. 13: 631-42. PMID: 25604267
- Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. | Kremyanskaya, M., et al. 2015. Expert Opin Pharmacother. 16: 1185-94. PMID: 25873215
- Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report. | Shimazu, Y. and Fujimura, K. 2016. Ann Hematol. 95: 1909-10. PMID: 27525727
- Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review. | Bohîlţea, RE., et al. 2017. Medicine (Baltimore). 96: e8735. PMID: 29145319
- Anagrelide for Gastrointestinal Stromal Tumor. | Pulkka, OP., et al. 2019. Clin Cancer Res. 25: 1676-1687. PMID: 30530703
Inhibitor of:
CD42c, Cyp3a41b, PDE, PDE1A, PDE1C, PDE6Aα, PDE6D, PDE6G, and TPO.Activator of:
α-protein kinase 3, ARA160, Atase, CASC1, CLCA5_Clac5, CNPase, CREST, Gm129, ICA1L, LEPROTL1, MC2-R, NIFK, NOC4L, NUDT3, OB-cadherin, PAPST1, PPEF-1, Psf1, SPACR, TAPBPL, TMEM118, TMEM25, Tra-2α, and WECHE.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Anagrelide hydrochloride, 10 mg | sc-203513 | 10 mg | $103.00 | |||
Anagrelide hydrochloride, 50 mg | sc-203513A | 50 mg | $587.00 |